Navigation Links
Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
Date:4/30/2013

SAN DIEGO, Calif. and OXFORD, England, April 30, 2013 /PRNewswire/ -- Glide Pharma® today announced the award of a sub-contract from Pfenex Inc. to develop a solid formulation containing the recombinant Protective Antigen (rPA) from Bacillus anthracis expressed in Pfenex Expression Technology™ suitable for delivery with the Glide SDI® (solid dose injector).  This approach will address two important logistical constraints of the currently available vaccine, namely, long term stability during storage and ease of administration.

The Pfenex project has been funded in whole with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201200033C.

Under an existing Biomedical Advanced Research and Development Authority (BARDA) contract, Pfenex has successfully developed a novel rPA that is highly immunogenic and protective in animal studies, with a scalable production process and robust yields.

"Glide Pharma is pleased to be working with Pfenex on this contract from NIAID.  We believe that a combination of Pfenex's proprietary rPA-based anthrax vaccine and Glide Pharma's novel formulations and delivery technology will provide a product suitable in response to an anthrax biothreat," stated Dr Mark Carnegie-Brown , CEO, Glide Pharma.

"We are pleased to award this sub-contract to Glide Pharma. Their novel formulation and delivery technology allows us to expand our anthrax vaccine program," stated Bertrand C. Liang , CEO, Pfenex. "Leveraging the Glide SDI® technology to develop an alternative delivery method of the Pfenex anthrax vaccine further supports our efforts to provide a safe, feasible and cost-effective solution to the United States government's quest to stockpile sufficient vaccine doses to rapidly respond to an anthrax biothreat."

For more information please visit http://www.pfenex.com/news/details/32

About Pfenex Inc.
Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare needs.  Utilizing the company's core technology, Pfenex Expression Technology™ for recombinant protein expression, Pfenex is able to rapidly develop and produce high quality therapeutics. In addition, Pfenex also produces and markets research proteins and reagent proteins for the research and drug development community through its Reagent Proteins division.  For more information please visit www.pfenex.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Nominierungen für BRAVE Awards werden ab jetzt entgegengenommen
2. BRAVE Awards Now Accepting Nominations
3. Bio-IT World Announces Best of Show Awards Finalists for the Bio-IT World Conference & Expo
4. Elsevier and the Belarus Ministry of Education Honor Researchers with Scopus Awards
5. American Federation for Aging Research Announces Recipients of Irving S. Wright and Vincent Cristofalo Scientific Awards
6. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
7. USP Global Fellowship Awards Program Call for Applications
8. 2012-2013 Michael E. DeBakey Journalism Awards Call for Entries
9. Indigo Biosystems Nominated for Two TechPoint Mira Awards for Technology Excellence and Innovation
10. TriLink BioTechnologies Awards Keck Science Department ResearchReward
11. Young Pathologists Receive Awards for Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
Breaking Biology News(10 mins):